Ortho RTi Announces More Prestigious Scientific Validation

- **Data from Ortho-R on Rotator Cuff study Presented at 2019 ORS Annual Meeting**
- **Data from Ortho-R and Cartilage repair study accepted for scientific publication in prestigious journal**

Kirkland, QC, February 4, 2019 – Ortho Regenerative Technologies Inc. ("**Ortho RTi**" or the "**Company"**), an emerging Orthopaedic and Sports Medicine Technology company, today announced that the results of two key scientific studies validating its product's ability to improve the repair of two distinct joint tissues - the rotator cuff tendon and articular cartilage.

On Sunday the Rotator Cuff study results were presented at the Annual Orthopaedic Research Society ("ORS") (http://www.ors.org) meeting. The ORS Annual Meeting attracts over 3,000 attendees with an interest in Orthopaedic research including clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who present the latest innovative and cutting-edge musculoskeletal research. This year's ORS Annual Meeting is being held this February 2-5 in Austin, Texas.

This presentation given by Marc Lavertu Ph.D, from Montreal's prestigious École Polytechnique, highlighted the results of a dose ranging study examining Ortho RTi's Ortho-R technology in the biologic repair of rotator cuff injuries. The study used MRI and histopathology (the microscopic examination of biological tissues in very fine detail), read by blinded experts, to compare the results of Ortho-R versus standard of care in a non-clinical rotator cuff injury model in sheep. It showed that Ortho-R improved rotator cuff healing processes in this large animal model, as revealed by MRI and trends of improved structural appearance of the tendon and enthesis at 12 weeks post-op.

The accepted peer reviewed journal article titled "Freeze-dried chitosan/PRP implants improve marrow stimulated cartilage repair in a chronic defect rabbit model" will appear in an upcoming edition of the Journal of Tissue Engineering and Regenerative Medicine.

"Our scientific evidence continues to excel and gather the attention of world experts. These are 2 more of our 16 peer-reviewed abstracts, posters, manuscripts and podium presentations in the last two years. Further, these are key publications resulting from work with experts at New York City's renowned Hospital for Special Surgery," said Ortho RTi's Chief Scientific Officer, Dr. Michael Buschmann

About Rotator Cuff Injury

The rotator cuff is the name given to the collection of four tendons that stabilize the shoulder joint. The tendons around the joint can suffer tears as a result of injury to the tendon or as a result of degeneration over time. Repetitive overhead activity is often associated with cuff tears. Symptoms include a dull, aching pain, and patients often suffer secondary symptoms including lack of sleep and weakness in the arms resulting from a lack of exercise. If conservative therapy is not successful, surgery will often be performed. The principal aim of surgical intervention is to reattach the torn tendon to the bone. The standard of care involves the use of suture anchors placed into the bone and the tendon

then being held in place with sutures. There are 4 million Americans with rotator cuff injuries, and all are at risk for disability. It is estimated that 25% of U.S. adults over the age of 40 will develop a rotator cuff tear, with aging 'weekend warriors' escalating the problem

About Cartilage Injury

Articular cartilage covers the ends of bones that form joints in the body. It provides lubrication so that the joints move smoothly with low friction and helps transmit mechanical load. Articular cartilage can be damaged by injury or through degenerative processes, which makes moving the joints difficult and painful (Osteoarthritis). Microfracture is a surgical repair technique that consists of drilling small channels into the bone under a cartilage defect. Although microfracture is currently the gold standard for treating small, focal cartilage lesions, it provides only short to mid-term relief since the repair tissue is usually of poor quality. In Canada alone, Osteoarthritis affects more than 10% of people aged 15 years and older with a total economic burden estimated at $405 billion by 2020. In the US, 1.7 million new cartilage injuries are detected annually with only 125,000 treated.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine biologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to tendons, meniscus, ligaments and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Considering the significant bio-activity and residency of our proprietary bio-polymer Ortho RTi continues to assess its potential for therapeutic uses outside of the soft tissue repair. Further information about Ortho RTi is available on the Company's website at www.orthorti.com and on SEDAR at www.sedar.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Brent Norton MD, MBA, ICD.D
Chief Executive Officer
514.782.0951
norton@orthorti.com